| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/18/2002 | US6406866 Competitive binding to mammalian methadone specific opiod receptors in cell expression |
| 06/18/2002 | US6406865 Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies |
| 06/18/2002 | US6406861 Viral diseases and immunogens |
| 06/18/2002 | US6406705 Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| 06/18/2002 | US6406704 Compounds and methods for treatment and diagnosis of mycobacterial infections |
| 06/18/2002 | US6406703 Treatment of H. pylori associated gastroduodenal disease |
| 06/18/2002 | US6406702 Multivalent in ovo avian vaccine |
| 06/18/2002 | US6406701 Reducing the susceptibility of t lymphocytes to hiv infection |
| 06/18/2002 | US6406699 Composition and method of cancer antigen immunotherapy |
| 06/18/2002 | US6406696 Activation of t cells, immunopotentiation and immunology, administering anti-cd3 monoclonal antibodies |
| 06/18/2002 | US6406695 Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody |
| 06/18/2002 | US6406694 Anti-CCR2 antibodies |
| 06/18/2002 | US6406689 Compositions and methods for treatment of tumors and metastatic diseases |
| 06/18/2002 | US6406679 Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells |
| 06/18/2002 | CA2098819C Dna sequences derived from the genome of the papillomavirus hpv39, their application to in vitro diagnostic and to the production of immunogen compositions |
| 06/18/2002 | CA2034611C Synthetic peptide compositions with immunoreactivities to antibodies to htlv |
| 06/18/2002 | CA2025019C Synthetic peptide compositions with immunoreactivities to antibodies to htlv-1 |
| 06/13/2002 | WO2002046477A2 Endogenous retroviruses up-regulated in prostate cancer |
| 06/13/2002 | WO2002046426A2 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor |
| 06/13/2002 | WO2002046416A2 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| 06/13/2002 | WO2002046411A2 Intestinal proteins |
| 06/13/2002 | WO2002046409A2 Proteins and nucleic acids encoding same |
| 06/13/2002 | WO2002046401A1 Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue |
| 06/13/2002 | WO2002046384A2 Kinases and phosphatases sequences, and use thereof |
| 06/13/2002 | WO2002046376A1 Dehydrated antigen presenting cells usable for vaccination |
| 06/13/2002 | WO2002046364A2 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 06/13/2002 | WO2002046238A2 Rationally designed antibodies |
| 06/13/2002 | WO2002046237A2 Humanized antibodies that recognize beta amyloid peptide |
| 06/13/2002 | WO2002046225A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | WO2002046224A2 Compositions and methods relating to lung specific genes and proteins |
| 06/13/2002 | WO2002046208A2 Method of producing biospecific molecules by protein trans-splicing |
| 06/13/2002 | WO2002045747A1 Immunotherapeutic combinations for the treatment of tumors |
| 06/13/2002 | WO2002045746A2 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens |
| 06/13/2002 | WO2002045745A2 Methods and vaccines for providing in ovo protection against turkey rhinotracheitis |
| 06/13/2002 | WO2002045743A2 Hcv vaccines |
| 06/13/2002 | WO2002045742A2 Lipoteichoic acid immunogenic compositions and methods of making and using thereof |
| 06/13/2002 | WO2002045741A2 Helicobacter pylori prime and boost vaccination comprising caga and nap antigens |
| 06/13/2002 | WO2002045740A1 Compositions containing gangliosides for use in the treatment of skin disorders |
| 06/13/2002 | WO2002045739A1 Immunomodulatory constructs and their uses |
| 06/13/2002 | WO2002045738A2 Vaccine composition containing transforming growth factor alpha |
| 06/13/2002 | WO2002045737A2 Methods of treatment involving human mda-7 |
| 06/13/2002 | WO2002045736A1 Methods for improved diagnosis and treatment of mycobacterial infections |
| 06/13/2002 | WO2002045735A2 Nrp-derived peptides useful for treating insulin-dependent diabetes mellitus |
| 06/13/2002 | WO2002045657A2 Ovarian tumor antigen and methods of use therefor |
| 06/13/2002 | WO2002045653A2 Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
| 06/13/2002 | WO2002024224A3 Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen |
| 06/13/2002 | WO2002020554A3 Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines |
| 06/13/2002 | WO2002020038A3 Method for down-regulating ige |
| 06/13/2002 | WO2002017857A3 Methods and compositions for inhibiting angiogenesis |
| 06/13/2002 | WO2002014357A3 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 06/13/2002 | WO2002010404A3 Regulation of human masp-like serine protease |
| 06/13/2002 | WO2002009746A3 Vaccines comprising outer membrane vesciles from gram negative bacteria |
| 06/13/2002 | WO2002008418A3 Method of isolation of regulated virulence determinants from bacterial pathogens |
| 06/13/2002 | WO2002004495A3 Streptococcus pyogenes antigen |
| 06/13/2002 | WO2002000252A3 Non-human animal models of tolerance to hepatitis c virus immunogenes |
| 06/13/2002 | WO2002000249A3 Multivalent vaccine composition |
| 06/13/2002 | WO2001098350A3 Compositions comprising net-4 modulations and their use for treating neoplastic disease |
| 06/13/2002 | WO2001098277A3 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 06/13/2002 | WO2001096377A3 Vaccine for congenital tremors in pigs |
| 06/13/2002 | WO2001093829A3 Powder compositions |
| 06/13/2002 | WO2001092294A3 Therapeutic anti-melanoma compounds |
| 06/13/2002 | WO2001087981A3 Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof |
| 06/13/2002 | WO2001083785A3 Regulated antigen delivery system (rads) involving bacteria |
| 06/13/2002 | WO2001078748A3 Immunomodulatory methods using carbohydrate antigens |
| 06/13/2002 | WO2001077168A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 06/13/2002 | WO2001072721A3 Synergistic methods and compositions for treating cancer |
| 06/13/2002 | WO2001072277A3 Immunotherapeutic methods and compositions |
| 06/13/2002 | WO2001044300A3 Brain specific binding members |
| 06/13/2002 | WO2001040280A3 Composition and method for treating a microbial infection |
| 06/13/2002 | WO2000077262A9 Synthetic ligation reassembly in directed evolution |
| 06/13/2002 | WO2000066741A3 Conserved neisserial antigens |
| 06/13/2002 | WO2000064400A9 Methods for treating congestive heart failure |
| 06/13/2002 | WO2000063350A9 Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis |
| 06/13/2002 | WO2000061736A9 Recombinant and mutant marek's disease virus |
| 06/13/2002 | WO2000037610A3 Expression of immunogenic hepatitis b surface antigens in transgenic plants |
| 06/13/2002 | US20020072596 Nucleotide sequences coding transrerrins; for use in the treatment of nervous system., blood abbd anemia, heme biosynthesis disorders |
| 06/13/2002 | US20020072595 Nucleic acid for use in kits for detection of preferential bacterial infection |
| 06/13/2002 | US20020072504 Method and reagents for genetic immunization |
| 06/13/2002 | US20020072495 LL-37 is an immunostimulant |
| 06/13/2002 | US20020072494 Angiogenesis inhibitor, K1-5 (protease-activated kringles 1-5) genetically engineered so it can be secreted from cells in which it is expressed; contains a secretory signal peptide and a pre-activation peptide derived from plasminogen |
| 06/13/2002 | US20020072493 To promote nerve regeneration or to confer neuroprotection by administering the T cells or a nervous system-specific antigen such as myelin basic protein |
| 06/13/2002 | US20020072107 Human osteoclast derived cathepsin |
| 06/13/2002 | US20020072091 Death domain containing receptor 5 |
| 06/13/2002 | US20020071851 Borrelia burgdorferi bacterin |
| 06/13/2002 | US20020071850 Helicobacter pylori antigen |
| 06/13/2002 | US20020071848 Inactivated influenza virus and a purified recombinant envelope protein from the virus, or a fragment or precursor thereof. |
| 06/13/2002 | US20020071847 Present on the surface of Borrelia burgdorferi cells that lack the outer membrane proteins OspA, OspB, OspC and OspD; sensitive to cleavage with proteinase K; having binding affinity for certain monoclonal antibodies |
| 06/13/2002 | US20020071846 Vaccines comprising oil bodies |
| 06/13/2002 | US20020071845 Vaccine for leptospirosis |
| 06/13/2002 | US20020071844 Acquired Immunodeficiency Syndrome in the human, Equine Infectious Anemia in the horse, and other viral diseases of man and animal, using at least an antiserum of equine origin. |
| 06/13/2002 | US20020071842 CD1 fusion proteins, preferably multivalent fusion proteins that are present in multimeric form (e.g., by Protein A binding multiple CD1 fusion proteins); diagnosis, vaccines |
| 06/13/2002 | US20020071840 Method of therapeutic administration of anti-CD40L compounds |
| 06/13/2002 | US20020071839 Downmodulating the immune response to an intestinal allograft in a subject comprising administering an antibody that binds to B7-1 and an antibody that binds to B7-2. |
| 06/13/2002 | US20020071833 Hematopoietic stem cell gene therapy |
| 06/13/2002 | US20020071832 Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| 06/13/2002 | US20020071831 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 06/13/2002 | US20020071829 Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
| 06/13/2002 | US20020071825 Methods and compositions for inducing an immune response |
| 06/13/2002 | US20020071807 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 06/13/2002 | DE10061334A1 Verwendung von aus embryonalen Stammzellen hergeleiteten Zellen zur Erhöhung der Transplantationstoleranz und zur Wiederherstellung zerstörten Gewebes Using derived from embryonic stem cells to increase transplant tolerance and restore damaged tissue |